<DOC>
	<DOCNO>NCT02850848</DOCNO>
	<brief_summary>A Randomized , Parallel , Single-Dose Study Evaluate Pharmacokinetics Test Formulation Entigin Film Coated Tablet 0.5mg ( Entecavir 0.5 mg ) , Compared Equivalent Dose Reference Drug Product ( Baraclude 0.5mg Tablets ) Healthy</brief_summary>
	<brief_title>Pharmacokinetics Two Formulations Entecavir</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>1 . Healthy adult , age 20 45 year old . 2 . Physically mentally healthy subject confirm interview , medical history , clinical examination , laboratory test , chest xray electrocardiogram . particular clinical significance clinical examination laboratory test within two month ( 60 day ) prior administration study medication . normal consider clinically significant investigator chest Xray Electrocardiogram ( ECG ) result within six month ( 180 day ) prior administration study medication . 3 . Body weight must 50 kg male 45 kg female . 4 . The normal range body mass index 18 30 ; body mass index equal [ weight ( kg ) ] / [ height ( ) ] 2 . 5 . Laboratory determination result within normal range consider clinically significant investigator , include : Serum Glutamic Oxaloacetic Transaminase ( SGOT , AST ) , Serum Glutamic Pyruvic Transaminase ( SGPT , ALT ) , albumin , glucose , creatinine , uric acid , cholesterol , Triglycerides ( TG ) , GammaGlutamylTranspeptidase ( Î³GT ) , alkaline phosphatase , total bilirubin , Blood Urea Nitrogen ( BUN ) , Hepatitis B surface antigen ( HBsAg ) , AntiHepatitis C virus ( HCV ) AntiHuman Immunodeficiency Virus ( HIV ) test . 6 . Hematology test result within normal range consider clinically significant investigator , include : hemoglobin , hematocrit , White Blood Cell ( WBC ) count , Red Blood Cell ( RBC ) count , platelet count WBC count differential . 7 . Urinalysis result within normal range consider clinically significant investigator , include : glucose , protein , RBC , WBC , epithelial cell , cast bacteria . 8 . Female subject : use adequate contraception since last menstruation plan conception study . nonlactating . negative pregnancy test ( urine ) prior study . 9 . Informed consent form sign . 1 . A history drug alcohol abuse past 24 week . 2 . Sensitivity analogous drug . 3 . A clinically significant illness ( lactic acidosis severe hepatomegaly steatosis ) within past 4 week . 4 . Evidence clinical significant renal , cardiovascular , hepatic , hematopoietic , neurological , pulmonary gastrointestinal pathology within past 4 week . 5 . Planned vaccination time course study . 6 . Participation clinical investigation last 60 day . 7 . Regular use medication last 4 week . 8 . Single use medication last 2 week . 9 . Blood donation 250 mL within past 12 week . 10 . Employees family sponsor and/or Contract Research Organization ( CRO ) company . 11 . Individuals judge investigator coinvestigator undesirable subject .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Pharmacokinetic</keyword>
</DOC>